Monday, 6 July 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 06 July 2026
News

MSAC delivers a No over price

Posted 6 July 2026 AM

Pfizer has been delivered a blow in its attempt to secure funding for Hympavzi under the National Blood Agreement (NBA), with MSAC knocking back the application after being unable to discern if the therapy “was good value for money”.

Hympavzi was one of two haemophilia treatments considered for funding under the NBA by MSAC at its April meeting, with a decision on Novo Nordisk’s Alhemo still pending.

To see the whole article, please login

Popular

Next era of blockbusters unveiled
Did this pharma disparage a rival?
Media frenzy bites AstraZeneca
MSAC delivers a No over price
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (22)

Access & Reimbursement (1)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (4)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home